## TENT COOPERATION TREATY

	From the INTERNATIONAL BUREAU
PCT	То:
NOTIFICATION OF THE RECORDING OF A CHANGE  (PCT Rule 92bis.1 and Administrative Instructions, Section 422)	HEIJLEK, Edward, J. Senniger, Powers, Leavitt & Roedel One Metropolitan Square 16th Floor St. Louis, MI 63102 ETATS-UNIS D'AMERIQUE
Date of mailing (day/month/year) 22 November 2001 (22.11.01)	
Applicant's or agent's file reference 3203/1/PCT	IMPORTANT NOTIFICATION
International application No. PCT/US00/09806	International filing date (day/month/year) 17 May 2000 (17.05.00)
The following indications appeared on record concerning:      The applicant the inventor	the agent the common representative
Name and Address MONSANTO COMPANY P.O. Box 5110	State of Nationality State of Residence US US
Chicago, IL 60680-5110 United States of America Chicago, IL 60680-5110 United States of America	Facsimile No.
	Teleprinter No.
2. The International Bureau hereby notifies the applicant that to the person X the name the add	
Name and Address PHARMACIA CORPORATION	State of Nationality State of Residence US US
P.O. Box 5110 Chicago, IL 60680-5110 United States of America	Telephone No.
St. Louis, MI 63102 United States of America	Facsimile No.
,	Teleprinter No.
3. Further observations, if necessary:	
4. A copy of this notification has been sent to:	
the International Searching Authority	the designated Offices concerned  X the elected Offices concerned
the International Preliminary Examining Authority	other:
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Beatriz LARGO
Faccimile No : (41-22) 740 14 35	Telephone No.: (41-22) 338.83.38

## P. ENT COOPERATION TREA

	From the INTERNATIONAL BUREAU
PCT	То:
NOTIFICATION OF ELECTION  (PCT Rule 61.2)  Date of mailing (day/month/year)	Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
06 February 2001 (06.02.01)	
International application No. PCT/US00/09806	Applicant's or agent's file reference 3203/1/PCT
International filing date (day/month/year) 17 May 2000 (17.05.00)	Priority date (day/month/year) 19 May 1999 (19.05.99)
Applicant	
SOUTH, Michael, S. et al	
The designated Office is hereby notified of its election mad	e:
X in the demand filed with the International Preliminan	· Examining Authority on
16 December	2000 (18.12.00)
in a notice effecting later election filed with the Inter	national Bureau on:
2. The election X was	
was not	
made before the expiration of 19 months from the priority Rule 32.2(b).	date or, where Rule 32 applies, within the time limit under
	•
The International Bureau of WIPO	Authorized officer

Facsimile No.: (41-22) 740.14.35

34, chemin des Colombettes

1211 Geneva 20, Switzerland

Claudio Borton

Telephone No.: (41-22) 338.83.38



PCT

REC'D 3 1 AUG 2001

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file 11289/kö	FOR FURTHE	TACTION	Notification of Transmittal of International minary Examination Report (Form PCT/IPEA/416)
International application	No. International filing of	ate (day/month/year)	Priority date (day/month/year)
PCT/US00/09806	17/05/2000		19/05/1999
International Patent Class C07D239/46  Applicant MONSANTO COM	ssification (IPC) or national classification ar	d IPC	
MONSANTO COM	-ANT et al.		
	preliminary examination report has be d to the applicant according to Article		s International Preliminary Examining Authority
2. This REPORT co	nsists of a total of 7 sheets, including	this cover sheet.	
been amende		d/or sheets containi	ription, claims and/or drawings which have ng rectifications made before this Authority der the PCT).
These annexes o	onsist of a total of sheets.		
3. This report contai	ns indications relating to the following	items:	
<u> </u>	of the report		
II Priorit	•		
	establishment of opinion with regard t	o novelty, inventive	step and industrial applicability
V ⊠ Reas	of unity of invention oned statement under Article 35(2) works and explanations suporting such :		, inventive step or industrial applicability;
	in documents cited		•
VII 🛛 Certa	in defects in the international applicat	ion	
VIII ⊠ Certa	in observations on the international a	oplication	
Date of submission of the	demand	Date of completi	on of this report
18/12/2000		29.08.2001	
Name and mailing addres	thority:	Authorized office	ST ST ADES MILVIUS
D-80298 Mu Tel. +49 89 2		Mathys, E	(the set of the set of
Fax: +49 89	•	Telephone No. +	49.89.2399.8596

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/09806

<ol> <li>Basis of the real</li> </ol>	eport
---------------------------------------	-------

•	tr. a.	ne receiving Office in	ments of the international application (Replacement sheets which have been furnished to response to an invitation under Article 14 are referred to in this report as "originally filed" to this report since they do not contain amendments (Rules 70.16 and 70.17)):
	1-	-177	as originally filed
	С	laims, No.:	
	1-	50	as originally filed
2	. w	ith regard to the lang	uage, all the elements marked above were available or furnished to this Authority in the
	lar	nguage in which the i	nternational application was filed, unless otherwise indicated under this item.
	Th	iese elements were a	vailable or furnished to this Authority in the following language: , which is:
		the language of a t	ranslation furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of pu	blication of the international application (under Rule 48.3(b)).
		the language of a t 55.2 and/or 55.3).	ranslation furnished for the purposes of international preliminary examination (under Rule
3.	Wi	th regard to any <b>nucl</b> ernational preliminary	eotide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:
		contained in the int	ernational application in written form.
		filed together with the	ne international application in computer readable form.
			ently to this Authority in written form.
		furnished subseque	ently to this Authority in computer readable form.
		The statement that	the subsequently furnished written sequence listing does not go beyond the disclosure in olication as filed has been furnished.
		The statement that listing has been furn	the information recorded in computer readable form is identical to the written sequence nished.
4.	The	e amendments have r	resulted in the cancellation of:
	$\Box$	the description,	pages:
		the claims,	Nos.:
		the drawings,	sheets:
5.		This report has beer considered to go be	n established as if (some of) the amendments had not been made, since they have been yond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/09806

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6	. Ad	ditional observations, if	necessa	ary:	
111	l. No	n-establishment of op	inion w	ith regar	rd to novelty, inventive step and industrial applicability
	The	e questions whether the	claimed	d inventio	on appears to be novel, to involve an inventive step (to be non-
		the entire international	applica	ition.	
	×	claims Nos. 40-49.			
be	ecau	se:			
	×	the said international a not require an internati see separate sheet	pplication	on, or the eliminary	e said claims Nos. relate to the following subject matter which does examination ( <i>specify</i> ):
		the description, claims that no meaningful opin	or draw nion cou	rings ( <i>ind</i> uld be forr	dicate particular elements below) or said claims Nos. are so unclear med (specify):
		the claims, or said clair could be formed.	ns Nos.	are so ii	inadequately supported by the description that no meaningful opinion
		no international search	report l	nas been	n established for the said claims Nos
2.	and	eaningful international p /or amino acid sequence ructions:	relimina e listing	ary exami to comply	nination cannot be carried out due to the failure of the nucleotide ly with the standard provided for in Annex C of the Administrative
		the written form has not	t been fi	urnished	or does not comply with the standard.
					en furnished or does not comply with the standard.
٧.	Rea citat	soned statement unde tions and explanations	r Article	e 35(2) w rting suc	with regard to novelty, inventive step or industrial applicability; ch statement
1.	State	ement			
	Nove	elty (N)	Yes: No:	Claims Claims	
	Inve	ntive step (IS)	Yes: No:	Claims Claims	
	Indu	strial applicability (IA)	Yes:	Claims	1-39,50

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/09806

No: Claims

2. Citations and explanations see separate sheet

#### VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted: see separate sheet

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

#### ITEM III

Claims 40-49 relate to subject matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT.

Consequently, no opinion will be formulated with respect to the industrial applicability of the subject matter of these claims (see Article 34(4)(a)(i) PCT (see also ITEM V).

#### ITEM V

### Novelty

The present compounds differ from the compounds disclosed by (D1) US-A-5 441 960 and (D2) WO-96/33974 in the arrangement of the structural elements of the Nsubstituent.

### Inventive Step

The problem underlying the present subject matter was the provision of further compounds inhibiting serine proteases of the coagulation cascade.

From compounds having the same utility disclosed by D1 and D2 the present ones differ in the arrangement of the structural elements of the N-substituent. This arrangement is, however, known from e.g. (D3) WO-A-97/01338 and (D4) WO-A-99/11267 (both documents cited in your application PCT/US00/08220) for corresponding pyridinone and pyrazinone derivatives. It is therefore considered to have been obvious to solve the problem by replacing the

N-substituent of compounds according to D1 and D2 by such ones known from D3 and D4 or the other way round by replacing in compounds according to D3 and D4 the pyridinone respectively pyrazinone by a similar azacycle known in the art, as pyrimidinone from D1 and D2.

Accordingly, the present subject matter does not fulfil the requirements of Article 33(3) of the PCT.

The above obviousness objection could be overcome if it were shown that present compounds exhibit unexpected properties (i.e. unexpectedly solve a problem not yet solved) when compared to the structurally closest related compounds known from the above mentioned state of the art.

Property establishing an inventive step must then extend to the whole of the scope

## **EXAMINATION REPORT - SEPARATE SHEET**

claimed. It is pointed out in this respect that an eventual solution of a problem establishing an inventive step based on the few present compounds having been shown to have an activity (see present description, Table 2 on page 176, for compounds wherein [SPEC0830], M, K, E<sup>0</sup>, and Y<sup>0</sup> are always -NH-, -CH<sub>2</sub>-, -CONH- respectively amidinobenzyl, B is phenyl, isopropyl or cyclobutyl, A is -CH<sub>2</sub>SO<sub>2</sub>or a bond and R<sup>2</sup> is phenyl, aminophenyl or pyridyl) could not at all imply that substantially all claimed alternatives to these working examples would also result in compounds solving said problem, since the best part of the listed myriad alternative substituents are not known in the art as obvious equivalents to the substantiated ones, i.e. an eventual inventive step could only be acknowledged for a scope representing a reasonable generalisation of the compounds shown to be a solution to the problem underlying the invention.

#### Industrial Applicability

For the assessment of present claims 40 to 49 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment (as present claim 50).

#### ITEM VII

The description does not mention the relevant background represented by the above cited documents as required by Rule 5.1(a)(ii) and (iii) PCT.

#### ITEM VIII

The drafting of the claims is not clear and concise as required by Article 6 PCT. In deciding this matter, regard has also to be had to the interest of the relevant public, since patents should not be allowed to erect a legal maze or smoke screen in front of potential users of the inventions to which they lay claim. Patent claims, taken singly as

### **INTERNATIONAL PRELIMINARY EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/09806

well as in totality, must be clear and concise in order to enable such potential users to ascertain, without undue burden, let alone recourse to litigation, whether their planned commercial use is likely to infringe the patent monopoly. Having to construe the present 50 claims with all their provisos and alternatives on more than 100 pages, and to form a valid and commercially useful opinion on whether or not any one of them could prevent or hinder the commercial activities must in the nature of things impose a severe and totally undue burden on the public. It follows that the present application as it stands falls foul of the clear provision not only of Rule 13(4) but also of Article 6 PCT.



PCT/US 00/09806

A CLAS	CENTON OF CUID TO THE			/ 03 00/ 09606
ĨPČ 7	SIFICATION OF SUBJECT MATTER C07D239/46 C07D253/06 C07D4 A61P9/00	401/04 CO7	D417/12	A61K31/505
According	to international Patent Classification (IPC) or to both national cla	neolficettes and 150		
B. FIELD	SSEARCHED			
IPC 7	documentation searched (classification system followed by class CO7D A61K A61P	iffcation symbols)	-	
Document	ation searched other than minimum documentation to the extent	that euch documents a	re included in the	he fields searched
Electronic	date base consulted during the International search (name of da	ta base and, where pr	actical, search to	Arms used)
CHEM /	ABS Data			
C. DOCUM	IENTS CONSIDERED TO BE RELEVANT			
Category •	Citation of document, with indication, where appropriate, of the	e relevant passanes		Referent to all 1 M
				Relevant to claim No.
A	US 5 441 960 A (P.R.BERNSTEIN) 15 August 1995 (1995-08-15)		,	1,8,16, 24, 32-34,
	column 1 -column 20; claims			38-41
A	WO 96 33974 A (THE GREEN CROSS CORPORATION) 31 October 1996 (1	996-10-31)	-	1,8,16, 24, 32-34,
	page 0; claims			38-41
				·
=	or documents are listed in the continuation of box C.	X Patent fan	nlly members an	e listed in annex.
document consider earlier do filling dat	Which may throw doubte on orderly, eleterical	ched to unders invention  "X" document of pa- cannot be con-	stand the principi rticular relevance Bidgred novel or	the international filing date lot with the application but le or theory underlying the e; the cizimed invention cannot be considered to
citation of document other me	or other special reason (as epecified)  I referring to an onel dischause uses gubilities as	"Y" document of par cannot be considerable to document is co ments, such co	rticular relevance sidered to involve embined with one	the document is taken alone s; the claimed invention e an inventive step when the e or more other such docu- p obvious to a person skilled
TOTO UIA	i die priority date dialined	in the art. "&" document memb		
	tual completion of the international search September 2000			nal search report
		29/09/	/2000	
ina and wa	iling address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijawijk Teil. (+31-70) 340-2040, Tx. 31 651 epo ni,	Authorized office		
DCT464.040	rax: (431-70) 340-3018	Franco	ois, J	1

Potent de sussesses		7		1 7 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
Patent document cited in search report		Publication date		Patent family member(s)	Publication date	
US 5441960	A	15-08-1995	AU CA DE DE EP FI WO HU JP NO ZA	3959593 A 2133659 A 69311804 D 69311804 T 0636141 A 944804 A 9321210 A 68402 A 7505876 T 943911 A 9302696 A	18-11-1993 28-10-1993 31-07-1997 27-11-1997 01-02-1995 12-10-1994 28-10-1993 28-06-1995 29-06-1995 14-10-1994 27-10-1993	
WO 9633974	Α .	31-10-1996	CA EP US	2219364 A 0826671 A 5948785 A	31-10-1996 04-03-1998 07-09-1999	